

Longitudinal characterisation of cell-mediated immune responses following influenza A(H5N8) vaccination

Sunday, September 13, 2026 6:18 PM (1 minute)

In 2023, Finland experienced a major outbreak of highly pathogenic avian influenza caused by clade 2.3.4.4b influenza A(H5N1) virus, with transmission from wild birds to fur farms. In June 2024, Finland became the first country to vaccinate occupational risk groups using the MF59-adjuvanted influenza A(H5N8) vaccine (A/Astrakhan/3212/2020, Seqirus). We aimed to characterise the quality and durability of cellular immune responses induced by this novel vaccine. Peripheral blood mononuclear cells were collected before vaccination and at 3 weeks, 6 months and 12 months after the second vaccine dose. Antigen-specific T-cell responses were analysed using an activation-induced marker assay following stimulation with overlapping H1, H5 and N8 peptide pools. Vaccine-induced B-cell responses were evaluated using ELISpot assay and flow cytometric detection of H5-specific memory B cells. Robust H5/N8-specific CD4⁺ T-cell responses and relatively weak CD8⁺ T-cell responses were observed. Cellular responses remained detectable 12 months after vaccination. Analyses also indicated induction of H5-specific memory B cells, with declining kinetics during follow-up. The influenza A(H5N8) vaccine induces durable cellular immune responses in individuals at occupational risk of avian influenza exposure. This research provides important information on the durability of influenza A(H5N8) vaccine -induced immunity, which supports future pandemic preparedness and avian influenza vaccine development.

Keywords

Avian influenza, Cellular immunity, Influenza A(H5N8) vaccine

Professional status of the speaker

PhD student

Junior scientist status

Yes, I am a junior scientist.

Registration ID

INF26- 56

Author: Ms MIKKONEN, Ulla (Institute of Biomedicine, University of Turku, Turku, Finland)

Co-authors: Ms PELTONIEMI, Emilia (Institute of Biomedicine, University of Turku, Turku, Finland); Mrs WINTER, Sophie (Institute of Biomedicine, University of Turku, Turku, Finland; InFlames Research Flagship Center, University of Turku, Turku, Finland); Dr REINHOLM, Arttu (Institute of Biomedicine, University of Turku, Turku, Finland); Dr BELIK, Milja (Institute of Biomedicine, University of Turku, Turku, Finland); Ms IAKUBOVSKAIA, Alina (Department of Physiology, University of Helsinki, Helsinki, Finland); Dr PASTERNAK, Arja (Department of Physiology, University of Helsinki, Helsinki, Finland); Prof. RITVOS, Olli (Department of Physiology, University of Helsinki, Helsinki, Finland); Ms LIEDES, Oona (Finnish Institute for Health and Welfare, Helsinki, Finland); Dr HAVERI, Anu (Finnish Institute for Health and Welfare, Helsinki, Finland); Ms VARA, Saimi (Finnish Institute for Health and Welfare, Helsinki, Finland); Dr MELIN, Merit (Finnish Institute for Health and Welfare, Helsinki, Finland); Dr KOLEHMAINEN, Pekka (Institute of Biomedicine, University of Turku, Turku, Finland; InFlames Research Flagship Center, University of Turku, Turku, Finland); Dr KAKKOLA, Laura (Institute of Biomedicine, University

of Turku, Turku, Finland; Clinical Microbiology, Turku University Hospital, Turku, Finland); Prof. JULKUNEN, Ilkka (Institute of Biomedicine, University of Turku, Turku, Finland; InFlames Research Flagship Center, University of Turku, Turku, Finland)

Presenter: Ms MIKKONEN, Ulla (Institute of Biomedicine, University of Turku, Turku, Finland)

Session Classification: Poster slam

Track Classification: Antivirals and Vaccines